Disease/Infection News

RSS

GM-SCF therapy can reduce flu symptoms and prevent death

New research on mice has shown that pulmonary administration of granulocyte macrophage-colony stimulating factor significantly reduces flu symptoms and prevents death after a lethal dose influenza virus.

22 Apr 2011

EPO doping drug can reduce cerebral malaria related deaths

Almost 3.3 billion people, half of the world's population, risk being infected with malaria. Despite having effective means against malaria, the WHO reports 250 million cases of malaria each year and more than 700,000 related deaths. Researchers at the University of Copenhagen have now discovered that EPO, the doping drug known from professional cycling, can significantly reduce cerebral malaria related deaths.

22 Apr 2011

Discovery of cancer drugs to kill malaria parasite could open up new strategies for treatment

Ahead of World Malaria Day (25 April), EU-funded researchers have discovered that drugs originally designed to inhibit the growth of cancer cells can also kill the parasite that causes malaria. They believe this discovery could open up a new strategy for combating this deadly disease, which, according to World Health Organisation statistics, infected around 225 million and killed nearly 800 000 people worldwide in 2009.

21 Apr 2011

WSU researcher develops potential vaccine for Chlamydia

A Wayne State University School of Medicine researcher has developed a potential first ever vaccine for Chlamydia, the world's most prevalent sexually transmitted disease and the leading cause of new cases of blindness.

21 Apr 2011

FDA warns four firms to stop making unproven MRSA prevention claims

The U.S. Food and Drug Administration issued four warning letters to companies that manufacture and market over-the-counter (OTC) drug products, including hand sanitizers, that claim to prevent infection from methicillin-resistant Staphylococcus aureus bacteria (MRSA).

21 Apr 2011

Rate of antiretroviral virological failure higher among children living with HIV/AIDS than adults, study finds

One in eight children living with HIV/AIDS "experiences triple-class virological failure - meaning the virus becomes resistant to multiple drugs - within five years of starting antiretroviral treatment," according to a study published Wednesday in the Lancet, HealthDay News/MSN reports. The "failure rate is higher than in adults and highlights the challenge of maintaining viral load suppression in young patients who begin antiretroviral therapy so early in life, the researchers said," according to the news service (Preidt, 4/19).

21 Apr 2011

Biomagnetics signs agreement with LANL to develop validated TB biomarker assay

Biomagnetics Diagnostics Corp., (PINK SHEETS: BMGP) a developer of revolutionary diagnostic systems and related technology for detecting HIV, hepatitis, tuberculosis, cholera and malaria, and other innovative technologies, today announced it has now completed a series of payments to Los Alamos National Laboratory (LANL) pursuant to the cooperative research and development agreement (CRADA) executed in 2010 between the two organizations.

21 Apr 2011

Antenatal infection and ventilation with BPD associated with excessive accumulation of dendritic cells in lungs

Rates of premature births have increased in recent years, affecting more than 12% of all births and making strategies for managing the associated perinatal complications an important public goal. Preterm infants are particularly at risk for bronchopulmonary dysplasia (BPD), a chronic lung disease. BPD has multiple causes, and uncovering critical interactions within the immune system can lead to new approaches for treatment.

21 Apr 2011

Opinions: Eliminating TB; HIV prevention trial; Reducing stillbirths; Foreign aid, global stability; Safe injection sites

In a U.S. News & World Report opinion piece, African Health Ministers Aaron Motsoaledi of South Africa, Mphu Ramatlapeng of Lesotho, and Benedict Xaba of Swaziland call upon the international community to join with them in the fight to rid the world of tuberculosis (TB). "That goal might seem overambitious or unrealistic. [But i]t's not," they write

21 Apr 2011

TRIM5 cellular protein helps rhesus monkeys resist HIV

Thanks to a certain protein, rhesus monkeys are resistant to HIV. Known as TRIM5, the protein prevents the HI virus from multiplying once it has entered the cell. Researchers from the universities of Geneva and Zurich have now discovered the protein's mechanism, as they report in Nature. This also opens up new prospects for fighting HIV in humans.

21 Apr 2011

Immigrant screening fails to detect more than 70% cases of latent tuberculosis infection

Current UK procedures to screen new immigrants for tuberculosis (TB) fail to detect more than 70 per cent of cases of latent infection, according to a new study published in The Lancet Infectious Diseases.

21 Apr 2011

Genetically modified mosquitoes tested to prevent spread of malaria: Study

According to the latest study in the journal Nature, researchers from Imperial College London and the University of Washington, Seattle found that after making specific genetic changes to a few mosquitoes and then allowing them to breed could eventually dramatically reduce the spread of the deadly disease malaria.

20 Apr 2011

$2.3 million of malaria medicines stolen

According to the Global Fund to Fight AIDS, Tuberculosis and Malaria, malaria medications valued at almost $2.3 million may have been stolen from government-run distribution centers in Africa and other locations.

20 Apr 2011

Gilead, MicroDose enter collaboration for inhalable small molecule antiviral fusion inhibitor MDT-637

Gilead Sciences, Inc. and MicroDose Therapeutx, Inc. today announced that the companies have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of MDT-637, MicroDose's inhalable small molecule antiviral fusion inhibitor for the treatment of respiratory syncytial virus (RSV).

20 Apr 2011

Mylan launches Famciclovir Tablets

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Famciclovir Tablets, 125 mg, 250 mg and 500 mg, the generic version of Novartis' Famvir® Tablets, a treatment for herpes.

20 Apr 2011

BIOTECH Development Partners provides funds to Biomagnetics

Biomagnetics Diagnostics Corp., (PINK SHEETS:BMGP) a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, cholera and malaria detection, and other innovative technologies, today announced it has begun receiving funds from a biotech-oriented investment group called BIOTECH Development Partners, LLC.

20 Apr 2011

Study shows possibility of women living with AIDS to breastfeed with lower risk

In low-income countries, 1.4 million women are living with the Aids virus. If no prevention measures are taken, the risk for future mothers of transmitting HIV to their child in utero, during delivery or when breastfeeding is 35%.

20 Apr 2011

Furiex acquires full rights to JNJ-Q2, a novel broad-spectrum fluoroquinolone antibiotic

Furiex Pharmaceuticals, Inc. announced today that it has acquired full exclusive license rights to develop and commercialize the compound JNJ-Q2 under its existing development and license agreement with Janssen Pharmaceutica N.V.. Furiex acquired these rights as a result of Janssen's decision not to exercise its option under the agreement that gave Janssen the opportunity to continue development of JNJ-Q2.

20 Apr 2011

Durata commences dalbavancin Phase 3 study in acute bacterial skin and skin structure infections

Durata Therapeutics today announced the Company initiated a global, pivotal, Phase 3 study (DISCOVER-1) of its lead product, dalbavancin, a long-acting, intravenous (IV) lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections (abSSSI). The pivotal study is being conducted under a Special Protocol Assessment (SPA) agreed upon with the U.S. Food and Drug Administration (FDA).

20 Apr 2011

Researchers to wind down HIV prevention trial in women after interim results find drug not offering protection from HIV

Researchers on Monday announced they were calling off a trial to test whether taking an oral HIV drug reduces the risk of HIV infection in women after interim analysis of the study showed women taking the medication were no less likely to become infected with HIV than those who were not taking the medicine, the Associated Press reports.

20 Apr 2011

Disease/Infection News

GM-SCF therapy can reduce flu symptoms and prevent death

EPO doping drug can reduce cerebral malaria related deaths

Discovery of cancer drugs to kill malaria parasite could open up new strategies for treatment

WSU researcher develops potential vaccine for Chlamydia

FDA warns four firms to stop making unproven MRSA prevention claims

Rate of antiretroviral virological failure higher among children living with HIV/AIDS than adults, study finds

Biomagnetics signs agreement with LANL to develop validated TB biomarker assay

Antenatal infection and ventilation with BPD associated with excessive accumulation of dendritic cells in lungs

Opinions: Eliminating TB; HIV prevention trial; Reducing stillbirths; Foreign aid, global stability; Safe injection sites

TRIM5 cellular protein helps rhesus monkeys resist HIV

Immigrant screening fails to detect more than 70% cases of latent tuberculosis infection

Genetically modified mosquitoes tested to prevent spread of malaria: Study

$2.3 million of malaria medicines stolen

Gilead, MicroDose enter collaboration for inhalable small molecule antiviral fusion inhibitor MDT-637

Mylan launches Famciclovir Tablets

BIOTECH Development Partners provides funds to Biomagnetics

Study shows possibility of women living with AIDS to breastfeed with lower risk

Furiex acquires full rights to JNJ-Q2, a novel broad-spectrum fluoroquinolone antibiotic

Durata commences dalbavancin Phase 3 study in acute bacterial skin and skin structure infections

Researchers to wind down HIV prevention trial in women after interim results find drug not offering protection from HIV

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Latest News